Design Therapeutics, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; balance-sheet comparisons are to December 31, 2020. Design Therapeutics is a preclinical-stage biopharmaceutical company developing GeneTAC small-molecule candidates for inherited nucleotide repeat expansion diseases. It has no approved products and has not generated product sales.
Key financial metrics
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Grant revenue | $0 | $31,000 | $0 | $173,000 |
| Research and development expense | $5.0 million | $1.1 million | $8.9 million | $1.4 million |
| General and administrative expense | $2.7 million | $0.4 million | $4.5 million | $0.8 million |
| Total operating expenses | $7.7 million | $1.5 million | $13.4 million | $2.3 million |
| Net loss | $7.6 million | $1.4 million | $13.2 million | $2.1 million |
| Basic and diluted net loss per share | $0.14 | $0.06 | $0.36 | $0.08 |
- Liquidity: At June 30, cash and cash equivalents were $370.8 million and available-for-sale investment securities were $32.0 million, totaling $402.8 million. Total current assets were $404.9 million; current liabilities were $3.4 million.
- Cash flow: For the first half of 2021, operating activities used $12.0 million; investing activities provided $1.5 million; financing activities provided $379.0 million. Cash and cash equivalents increased by $368.5 million.
- Equity and debt: Stockholders’ equity was $401.6 million, compared with a deficit of $11.3 million at year-end 2020. The filing reports no outstanding borrowing at June 30, 2021. Preferred shares converted to common stock in connection with the IPO.
- Margins: Not meaningful; the company had no product revenue and reported operating losses.
Material changes versus the prior comparable period
- First-half net loss increased by $11.0 million year over year, as R&D and G&A expenses rose substantially; grant revenue was nil after prior-year grant awards had been fully recognized.
- Management attributed higher R&D costs primarily to advancement of the Friedreich ataxia (FA) program, chemistry and manufacturing development, work on the myotonic dystrophy type-1 (DM1) program, and increased personnel. Higher G&A reflected staffing, public-company costs, insurance, professional fees, and stock-based compensation.
- Cash resources rose sharply following the January 2021 Series B financing, which generated approximately $124.7 million net, and the March 2021 IPO, which generated $254.3 million net. The IPO sold 13.8 million shares at $20 per share.
Outlook, commentary and risks
- Management expects operating expenses and losses to increase as it advances preclinical programs, prepares for clinical development, expands capabilities, and bears public-company and facility costs. It does not provide revenue or earnings guidance.
- The company said existing cash, cash equivalents and investments were expected to fund operations and capital requirements for at least 12 months following the filing. It also stated that current resources would not fund candidates through regulatory approval and that substantial additional capital would be needed.
- Management reported IND-enabling studies underway for two FA candidates and anticipated first-in-human dosing in FA patients in the first half of 2022, subject to regulatory clearance and candidate selection. It expected to complete DM1 IND-enabling studies and seek clearance for a first-in-human trial in 2023, and intended to declare another candidate in 2023. These are forward-looking plans, not assured milestones.
- Preclinical findings described by the company included restoration of frataxin levels in FA patient cells and increased endogenous frataxin expression in an animal model; DM1 studies showed reduced nuclear foci in patient muscle cells. No candidate had entered human trials.
- Principal risks include early-stage development and uncertain translation of preclinical results, clinical and regulatory delay or failure, novel technology and manufacturing challenges, reliance on third-party research and manufacturing, competition, intellectual-property uncertainty, and potential effects of COVID-19.
- A related-party lease signed in February 2021 covers approximately 12,370 square feet of laboratory and office space, expected to commence September 1, 2021 for 72 months. Minimum future payments disclosed were $4.7 million, before operating expenses and taxes; the landlord is controlled by the executive chairperson and co-founder. The filing also discloses consulting arrangements with co-founders and related parties.
- No material litigation or contingent liabilities were reported. The company reported effective disclosure controls as of June 30, 2021 and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether FA IND-enabling work and the anticipated first-in-human timing remain on track, and what regulatory conditions or candidate-selection decisions affect the timeline.
- How quickly cash and investments are being consumed relative to the stated runway, and the timing, terms and dilution implications of future financing.
- Whether reported preclinical findings are reproducible and translate into acceptable safety and efficacy in human studies.
- The terms, governance and ongoing costs of the related-party lease and consulting arrangements, including any potential termination fee under the consulting agreement.
- The potential effect of IPO lock-up expirations and registered resale rights on share supply; the filing noted that substantial shares could become eligible for sale beginning in September 2021.